Edition:
United Kingdom

Enzo Biochem Inc (ENZ.N)

ENZ.N on New York Stock Exchange

3.54USD
7:30pm BST
Change (% chg)

$-0.10 (-2.75%)
Prev Close
$3.64
Open
$3.63
Day's High
$3.71
Day's Low
$3.52
Volume
19,442
Avg. Vol
50,474
52-wk High
$4.81
52-wk Low
$2.33

Latest Key Developments (Source: Significant Developments)

Enzo Biochem Reports Fiscal Third Quarter And Nine Months Operating Results
Monday, 10 Jun 2019 

June 10 (Reuters) - Enzo Biochem Inc ::ENZO BIOCHEM REPORTS FISCAL THIRD QUARTER AND NINE MONTHS OPERATING RESULTS.Q3 NON-GAAP LOSS PER SHARE $0.14.Q3 GAAP EARNINGS PER SHARE $0.47.Q3 REVENUE $19.7 MILLION VERSUS $25.2 MILLION.INTELLECTUAL PROPERTY SETTLEMENTS GENERATE APPROXIMATELY $30 MILLION IN CASH IN Q3.EXPECT TO SEE MEANINGFUL SEQUENTIAL QUARTERLY COST REDUCTION IMPROVEMENT THROUGHOUT FISCAL 2020.ASSUMING NO FURTHER CHANGES IN REIMBURSEMENT PROGRAMS, RETURN TO OPERATING PROFITABILITY AT LABS IN EARLY CALENDAR 2020..ENZO BIOCHEM - IN ACTIVE DISCUSSIONS WITH SEVERAL LIFE SCIENCES & MEDICAL DEVICE COS, MANUFACTURERS OF AUTOMATED SYSTEMS FOR STRATEGIC RELATIONSHIPS.ENZO BIOCHEM - DISCUSSIONS INVOLVE DEVELOPING LONG-TERM RELATIONSHIPS IN AUTOMATION & MANUFACTURING, DISTRIBUTION, MARKETING & PRODUCT SALES.  Full Article

Enzo Biochem Says Co's Unit Enters Into Settlement, License Agreement With Hologic, Grifols S.A
Monday, 22 Apr 2019 

April 22 (Reuters) - Enzo Biochem Inc ::ENZO BIOCHEM - UNIT ENTERED INTO SETTLEMENT, LICENSE AGREEMENT WITH HOLOGIC, GRIFOLS S.A TO SETTLE ALL OUTSTANDING PATENT DISPUTES AMONG THE PARTIES.ENZO BIOCHEM - TERMS OF AGREEMENT INCLUDE ONE-TIME PAYMENTS OF $14 MILLION TO CO IN EXCHANGE FOR FULLY PAID-UP, WORLDWIDE LICENSES TO HOLOGIC & GRIFOLS.  Full Article

Harbert Fund Advisors Inc Reports 6.92 Pct Share Stake In Enzo Biochem Inc As Of March 29
Monday, 8 Apr 2019 

April 8 (Reuters) - Enzo Biochem Inc ::HARBERT FUND ADVISORS INC REPORTS 6.92 PERCENT SHARE STAKE IN ENZO BIOCHEM INC AS OF MARCH 29 - SEC FILING.HARBERT FUND ADVISORS INC SAYS PURCHASED SECURITIES OF ENZO BIOCHEM INC BASED ON BELIEF THAT SECURITIES WERE "UNDERVALUED".  Full Article

Enzo Biochem Reports Q2 Non-GAAP Loss Per Share of $0.18
Monday, 11 Mar 2019 

March 11 (Reuters) - Enzo Biochem Inc ::ENZO BIOCHEM REPORTS SECOND FISCAL QUARTER AND FIRST HALF 2019 RESULTS AND REPORTS PROGRESS ON ITS INVESTMENTS AND STRATEGIC GOALS.Q2 REVENUE $19.3 MILLION VERSUS $26.1 MILLION.Q2 NON-GAAP LOSS PER SHARE $0.18.  Full Article

Enzo Biochem Q1 Non-GAAP Loss Per Share $0.01
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Enzo Biochem Inc ::ENZO BIOCHEM REPORTS IMPROVED FIRST QUARTER RESULTS.Q1 NON-GAAP LOSS PER SHARE $0.01.Q1 REVENUE $27.7 MILLION VERSUS $26.3 MILLION.  Full Article

‍Enzo Biochem announces NYS department of health's approval of a new women's health infectious disease panel​
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Enzo Biochem Inc ::‍Enzo Biochem announces NYS department of health's approval of a new women's health infectious disease panel​.  Full Article

BRIEF-Enzo Biochem Says CO Considering All Available Options For Challenging Federal Circuit Panel's Decision

* ENZO BIOCHEM - U.S. COURT OF APPEALS ISSUED OPINION AFFIRMING LOWER COURT JUDGMENTS OF PATENT INVALIDITY FOR U.S. PATENT NOS. 6,992,180 & 8,097,405